ZyVersa Therapeutics, Inc. (ZVSA) 10-Year Financial Performance & Capital Metrics

ZVSA • • Industrial / General

HealthcareBiotechnologyAutoimmune & Inflammatory DiseasesDermatology & Autoimmune

AboutZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.Show more

Revenue $0
EBITDA -$9.14B -63304.5%
Net Income -$9.41B -9476.4%
EPS (Diluted) -8.48 +99.2%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -96099.37% -54192.4%
ROIC -91789.94% -433349.9%
Debt/Equity -
Interest Coverage -33858.18

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Low quality earnings: Net income not backed by cash flow
✗Shares diluted 100.0% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM67.17%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-92779.65%

EPS CAGR

10Y-

5Y-

3Y-

TTM88.28%

ROCE

10Y Avg-28631.22%

5Y Avg-28631.22%

3Y Avg-28631.22%

Latest-85841.77%

Peer Comparison

Dermatology & Autoimmune

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
AUPHAurinia Pharmaceuticals Inc.	1.96B	14.87	378.37	33.97%	29.28%	21.28%	2.25%	0.21
ARGXargenx SE	50.33B	813.24	63.63	78.6%	23.34%	15.14%		0.01
INVAInnoviva, Inc.	1.48B	19.76	54.89	15.54%	32.78%	12.61%	12.75%	0.65
GLPGGalapagos N.V.	2.24B	34.03	30.38	14.99%	-151.94%	-15.16%		0.00
PTGXProtagonist Therapeutics, Inc.	5.3B	84.75	20.04	6.24%	21.94%	7.11%	3.45%	0.02
ALMSAlumis Inc. Common Stock	2.84B	24.17	-2.33		-11.08%	-63.71%		0.12
PHATPhathom Pharmaceuticals, Inc.	1.17B	14.98	-2.83	80.01%	-186.53%
ORKAOruka Therapeutics, Inc.	1.57B	32.50	-6.51			-22.44%		0.00

Profit & Loss

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0
Revenue Growth %	-	-	-	-	-
Cost of Goods Sold+	10.4K	10.4K	10.4K	10.4K	6.93K
COGS % of Revenue	-	-	-	-	-
Gross Profit+	-10.4K	-10.4K	-10.4K	-10.4K	-6.93K
Gross Margin %	-	-	-	-	-
Gross Profit Growth %	-	0%	0%	0%	0.33%
Operating Expenses+	11.83M	7.7M	13.82M	14.41M	9.13M
OpEx % of Revenue	-	-	-	-	-
Selling, General & Admin	5.36M	5.58M	7.61M	11.2M	7.36B
SG&A % of Revenue	-	-	-	-	-
Research & Development	6.47M	2.12M	5.41M	3.21M	1.78B
R&D % of Revenue	-	-	-	-	-
Other Operating Expenses	0	0	809.67K	0	-9.13B
Operating Income+	-11.83M	-7.7M	-13.83M	-14.42M	-9.14B
Operating Margin %	-	-	-	-	-
Operating Income Growth %	-	0.35%	-0.8%	-0.04%	-632.59%
EBITDA+	-11.82M	-7.69M	-13.82M	-14.41M	-9.14B
EBITDA Margin %	-	-	-	-	-
EBITDA Growth %	-	0.35%	-0.8%	-0.04%	-633.05%
D&A (Non-Cash Add-back)	10.4K	10.4K	10.4K	10.4K	6.93K
EBIT	-12.17M	-7.26M	-14.44M	-107.75M	-9.15B
Net Interest Income+	-515.93K	-820.54K	-427.11K	457	-269.86K
Interest Income	516	821	428	457	0
Interest Expense	516.45K	821.37K	427.54K	0	269.86K
Other Income/Expense	-850.11K	-379.79K	-1.03M	-93.33M	-283.35M
Pretax Income+	-12.68M	-8.08M	-14.87M	-107.75M	-9.42B
Pretax Margin %	-	-	-	-	-
Income Tax+	0	0	-745.05K	-9.46M	-6.75M
Effective Tax Rate %	1%	1%	0.94%	0.91%	1%
Net Income+	-12.68M	-8.08M	-14.05M	-98.3M	-9.41B
Net Margin %	-	-	-	-	-
Net Income Growth %	-	0.36%	-0.74%	-6%	-94.76%
Net Income (Continuing)	-12.68M	-8.08M	-14.12M	-98.3M	-9.41B
Discontinued Operations	0	0	0	0	0
Minority Interest	0	0	0	0	0
EPS (Diluted)+	-272.45	-173.66	-930.25	-1089.66	-8.48
EPS Growth %	-	0.36%	-4.36%	-0.17%	0.99%
EPS (Basic)	-272.45	-173.66	-930.25	-1089.66	-8.48
Diluted Shares Outstanding	46.55K	46.55K	25.95K	97.5K	1.11M
Basic Shares Outstanding	46.55K	46.55K	25.95K	97.5K	1.11M
Dividend Payout Ratio	-	-	-	-	-

Balance Sheet

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	339.11K	811.78K	6.36M	3.35M	1.72M
Cash & Short-Term Investments	174.67K	328.58K	5.9M	3.14M	1.53M
Cash Only	174.67K	328.58K	5.9M	3.14M	1.53M
Short-Term Investments	0	0	0	0	0
Accounts Receivable	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-
Inventory	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-
Other Current Assets	164.44K	483.2K	460.35K	215.46K	184.87K
Total Non-Current Assets+	346.46K	314.39K	112.14M	18.76M	18.88M
Property, Plant & Equipment	38.13K	27.73K	115.7K	14.77K	0
Fixed Asset Turnover	-	-	-	-	-
Goodwill	0	0	11.9M	0	0
Intangible Assets	0	0	100.09M	18.65M	18.65M
Long-Term Investments	0	0	0	0	0
Other Non-Current Assets	308.32K	286.66K	46.66K	98.48K	235.71K
Total Assets+	685.57K	1.13M	118.51M	22.11M	20.6M
Asset Turnover	-	-	-	-	-
Asset Growth %	-	0.64%	104.23%	-0.81%	-0.07%
Total Current Liabilities+	7.56M	13.63M	8.19M	10.19M	11.23M
Accounts Payable	2.31M	2M	6.03M	8.43M	9.34M
Days Payables Outstanding	81.14K	70.2K	211.48K	295.92K	491.58K
Short-Term Debt	2.13M	9.15M	108.76K	8.66K	0
Deferred Revenue (Current)	20.5K	16.91K	0	0	0
Other Current Liabilities	2.18M	2.46M	1.36M	1.09M	854.7K
Current Ratio	0.04x	0.06x	0.78x	0.33x	0.15x
Quick Ratio	0.04x	0.06x	0.78x	0.33x	0.15x
Cash Conversion Cycle	-	-	-	-	-
Total Non-Current Liabilities+	1.69M	0	10.32M	844.91K	851.66K
Long-Term Debt	1.69M	0	0	0	0
Capital Lease Obligations	0	0	0	0	0
Deferred Tax Liabilities	0	0	10.32M	844.91K	851.66K
Other Non-Current Liabilities	0	0	0	0	0
Total Liabilities	9.24M	13.63M	18.51M	11.04M	12.08M
Total Debt+	3.82M	9.15M	108.76K	8.66K	0
Net Debt	3.64M	8.82M	-5.79M	-3.13M	-1.53M
Debt / Equity	-	-	0.00x	0.00x	-
Debt / EBITDA	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-
Interest Coverage	-22.91x	-9.38x	-32.36x	-	-33858.18x
Total Equity+	-8.56M	-12.5M	99.99M	11.07M	8.52M
Equity Growth %	-	-0.46%	9%	-0.89%	-0.23%
Book Value per Share	-183.83	-268.52	3853.64	113.58	7.67
Total Shareholders' Equity	-8.56M	-12.5M	99.99M	11.07M	8.52M
Common Stock	242	242	902	405	251
Retained Earnings	-44.81M	-52.9M	-4.92M	-103.22M	-112.63M
Treasury Stock	0	0	0	-7.17K	-7.17K
Accumulated OCI	0	0	0	0	0
Minority Interest	0	0	0	0	0

Cash Flow

	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-5.11M	-5.08M	-4.89M	-8.72M	-7.56M
Operating CF Margin %	-	-	-	-	-
Operating CF Growth %	-	0.01%	0.04%	-0.78%	0.13%
Net Income	-12.68M	-8.08M	-14.05M	-98.3M	-9.41M
Depreciation & Amortization	10.4K	10.4K	9.87K	10.4K	6.93K
Stock-Based Compensation	3.83M	4.14M	3.52M	1.19M	705.57K
Deferred Taxes	333.66K	-441.58K	-745.05K	-9.48M	6.75K
Other Non-Cash Items	288.37K	317.83K	-1.92M	95.25M	204.61K
Working Capital Changes	3.11M	-1.02M	8.29M	2.6M	929.88K
Change in Receivables	0	0	0	0	0
Change in Inventory	0	0	0	0	0
Change in Payables	-601.47K	-311.86K	6.62M	2.41M	750.57K
Cash from Investing+	0	0	0	0	0
Capital Expenditures	0	0	0	0	0
CapEx % of Revenue	-	-	-	-	-
Acquisitions	-	-	-	-	-
Investments	-	-	-	-	-
Other Investing	0	0	0	0	0
Cash from Financing+	4.56M	5.23M	1.87M	5.96M	5.95M
Debt Issued (Net)	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-
Dividends Paid	0	0	0	0	0
Share Repurchases	-	-	-	-	-
Other Financing	-126.4K	0	0	-1.46M	0
Net Change in Cash	-	-	-	-	-
Free Cash Flow+	-5.11M	-5.08M	-1.49M	-8.72M	-7.56M
FCF Margin %	-	-	-	-	-
FCF Growth %	-	0.01%	0.71%	-4.83%	0.13%
FCF per Share	-109.77	-109.04	-57.60	-89.44	-6.81
FCF Conversion (FCF/Net Income)	0.40x	0.63x	0.35x	0.09x	0.00x
Interest Paid	0	0	0	0	0
Taxes Paid	0	0	0	0	0

Key Ratios

Metric	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-32.11%	-177%	-96099.37%
Return on Invested Capital (ROIC)	-	-	-22.92%	-21.18%	-91789.94%
Debt / Equity	-	-	0.00x	0.00x	-
Interest Coverage	-22.91x	-9.38x	-32.36x	-	-33858.18x
FCF Conversion	0.40x	0.63x	0.35x	0.09x	0.00x

Frequently Asked Questions

Growth & Financials

ZyVersa Therapeutics, Inc. (ZVSA) reported $0.0M in revenue for fiscal year 2024.

ZyVersa Therapeutics, Inc. (ZVSA) grew revenue by 0.0% over the past year. Growth has been modest.

ZyVersa Therapeutics, Inc. (ZVSA) reported a net loss of $19.81B for fiscal year 2024.

Dividend & Returns

ZyVersa Therapeutics, Inc. (ZVSA) has a return on equity (ROE) of -96099.4%. Negative ROE indicates the company is unprofitable.

ZyVersa Therapeutics, Inc. (ZVSA) had negative free cash flow of $4.70B in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener